Frank G. Haluska

Sort by:

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Tom J. Lynch, Daphne W Bell, +11 authors Daniel A. Haber
The New England journal of medicine
2004

BACKGROUND Most patients with non-small-cell lung cancer have no response to the tyrosine kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR). However, about 10… (More)

Ponatinib in refractory Philadelphia chromosome-positive leukemias.

Jorge E. Cortes, Hagop A Kantarjian, +13 authors Moshe Talpaz
The New England journal of medicine
2012

BACKGROUND Resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL) is frequently… (More)

A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.

Jorge E. Cortes, D. Kim, +27 authors Hagop A Kantarjian
The New England journal of medicine
2013

BACKGROUND Ponatinib is a potent oral tyrosine kinase inhibitor of unmutated and mutated BCR-ABL, including BCR-ABL with the tyrosine kinase inhibitor-refractory threonine-to-isoleucine mutation at… (More)

Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma.

Hensin Tsao, Vikas Goel, Heng Wu, Guang Yang, Frank G. Haluska
The Journal of investigative dermatology
2004

Extant evidence implicates growth factor signaling in the pathogenesis of many tumor types, including cutaneous melanoma. Recently, reciprocal activating mutations of NRAS and BRAF were found in… (More)

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients.

Frank Stephen Hodi, Marcus O Butler, +17 authors Glenn Dranoff
Proceedings of the National Academy of Sciences…
2008

Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) functions as a negative regulator of endogenous and vaccine-induced antitumor immunity. The administration of fully human anti-CTLA-4 blocking… (More)

PTEN signaling pathways in melanoma

Phosphatase and tensin homolog deleted in from chromosome ten (PTEN), initially also known as mutated in multiple advanced cancers or TGF-β-regulated and epithelia cell-enriched phosphatase, is a… (More)

Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines.

Hensin Tsao, Xin Zhang, K Fowlkes, Frank G. Haluska
Cancer research
2000

Both inactivation of the tumor suppressor gene, PTEN/MMAC1, and oncogenic activation of RAS have been described in human cutaneous melanoma. In mice, activation of a RAS-containing pathway is a… (More)

Analysis of human transcriptomes

Victor E. Velculescu, Stephen L. Madden, +31 authors Kenneth W. Kinzler
Nature Genetics
1999

nature genetics • volume 23 • december 1999 387 The term ‘synteny’ (or syntenic) refers to gene loci on the same chromosome regardless of whether or not they are genetically linked by classic linkage… (More)

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients.

Frank Stephen Hodi, Martin C. Mihm, +14 authors Glenn Dranoff
Proceedings of the National Academy of Sciences…
2003

A large number of cancer-associated gene products evoke immune recognition, but host reactions rarely impede disease progression. The weak immunogenicity of nascent tumors contributes to this failure… (More)

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.

Agop Y. Bedikian, Michael Millward, +9 authors Frank G. Haluska
Journal of clinical oncology : official journal…
2006

PURPOSE Chemotherapy resistance in melanoma has been linked to antiapoptotic effects mediated by Bcl-2 protein. We evaluated whether targeting Bcl-2 using an antisense oligonucleotide (oblimersen… (More)

Filter Results:

Publication Year

Publication Type

Co-author

Journals and Conferences